Collegium Pharmaceutical

Collegium Pharmaceutical, Inc. operates as a pharmaceutical company. The firm engages in the development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR. The Xtampza ER provides pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. The Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy. The Nucynta IR is a release formulation of tapentadol indicated for the management of acute pain severe enough to require an opioid analgesic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Collegium Pharmaceutical reports record 2022 performance and outlines growth strategies

Collegium Pharmaceutical's strong 2022 performance and strategic acquisitions position it for continued success in 2023 with a focus on growth.
The company's commercial strengths in key products like BELBUCA and Xtampza ER drive revenue and showcase growth potential.
Challenges in managing leverage, accelerating franchise growth, and navigating market dynamics are balanced by opportunities for expansion and innovation.
Analysts' inquiries reflect interest in Collegium Pharmaceutical's strategies, market positioning, and response to regulatory changes for future growth.

Collegium Pharmaceutical reports record Q1 revenue amidst patent challenges

Collegium Pharmaceutical's Q1 2023 performance showcased record revenue and strong financial management strategies.
The company faces challenges from patent infringement risks and generic competition, requiring a focus on defending IP and market positioning.
Opportunities in volume growth, business development, and strategic investments in key products position Collegium for long-term success.
Maintaining a balance between defending IP, managing expenses, and driving growth will be crucial for Collegium's future performance.

Collegium Pharmaceutical posts record revenue and growth, eyes strategic acquisitions

Collegium Pharmaceutical reported strong financial performance in Q2 2023, with a focus on achieving a banner year. Despite challenges with Xtampza ER and growth expectations, the company remains committed to improving access, reducing debt, and returning capital to shareholders.

Collegium Pharmaceutical excels in Q3, eyes growth opportunities ahead

Collegium Pharmaceutical reports strong Q3 2023 performance with record revenue and EBITDA growth, driven by successful contract renegotiations and operational efficiency.
Challenges include mitigating declining scripts, navigating patient profiles, and sustaining growth amidst market uncertainties, requiring strategic adjustments and foresight.
Opportunities lie in Medicare Part D market expansion, differentiated asset focus, and strategic valuations, positioning Collegium for future growth and market leadership.

Collegium Pharmaceutical reports record revenue and strategic wins in pain management market

Collegium Pharmaceutical's Q4 2023 earnings call highlighted exceptional financial achievements, robust product performance, and strategic wins in the pain management market. While facing challenges in maintaining guidance and addressing analyst queries, the company remains optimistic about its future outlook and growth potential.

Collegium Pharmaceutical reports strong Q1 earnings amidst leadership transition

Collegium Pharmaceutical's Q1 2024 earnings call highlighted strong financial performance, leadership transition, and growth strategies.
Despite challenges such as CEO resignation and competitive landscape dynamics, the company remains focused on its market position and growth potential.
Opportunities for business development priorities and strategic partnerships offer avenues for future growth and expansion.

Collegium Pharmaceutical reports record Q3 performance and navigates market challenges

Collegium Pharmaceutical's Q3 performance showcased robust financial results and strategic moves to strengthen their market position. While facing challenges in formulary changes and market competition, the company is well-positioned to leverage opportunities in the ADHD market and drive continued growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. The company was founded by Michael Thomas Heffernan in April 2002 and is headquartered in Stoughton, MA.

STOUGHTON, Mass., Feb. 07, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the pricing of its offering of $210,000,000 aggregate principal amount of 2.875% convertible senior notes due 2029 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering was upsized from the previously announced offering size of $175,000,000 aggregate principal amount of notes. Collegium also granted the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $31,500,000 principal amount of notes. The sale of the notes to the initial purchasers is expected to settle on February 10, 2023, subject to customary closing conditions.

Collegium Pharmaceutical, Inc. Prices Upsized $210.0 Million Convertible Senior Notes Offering

STOUGHTON, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced its intention to offer, subject to market and other conditions, $175,000,000 aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Collegium also expects to grant the initial purchaser of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $26,250,000 principal amount of notes.

Collegium Pharmaceutical, Inc. Announces Proposed Convertible Senior Notes Offering

-Results at or above high-end of 2022 earnings guidance-

Collegium Announces Fourth Quarter and Full Year 2022 Preliminary Financial Results

Jabil

Let's explore a Zacks screen that helps investors find 'Strong Buy' stocks trading near their highs as we head into February

Find 'Strong Buy' Stocks Near their Highs for February

Axcelis Technologies

MercadoLibre

Pinduoduo Inc - ADR

Shinhan Financial Group

Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are MELI, ACLS, SHG, PDD and COLL.

5 Stocks With Recent Price Strength Amid January Rally

Liberty Oilfield Services

Reinsurance Group of America

RGA, JBL, LBRT, CGAU and COLL are a few high earnings yield value stocks that could be good additions to your portfolio now.

Lift Portfolio Value With These 5 High Earnings Yield Picks

Zoetis

COLL vs. ZTS: Which Stock Is the Better Value Option?

– Product Revenues, Net Expected in the Range of $565.0 Million to $580.0 Million –

Collegium Provides 2023 Financial Guidance

Ruling bars ANDA filer Alvogen from entering market until 2032 patent expiry Ruling bars ANDA filer Alvogen from entering market until 2032 patent expiry

Appeals Court Affirms Validity of Collegium's Belbuca® Patents

STOUGHTON, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that management will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference being held in New York, NY from November 29 to December 1, 2022.

Collegium to Participate in Piper Sandler 34th Annual Healthcare Conference

My Collegium Pharmaceutical position has been gathering thanks to the ticker trading between my Buy and Sell Targets. The company's Q3 earnings beat has forced me to update my strategy. Collegium's new products from the BDSI acquisition have already helped the company report record revenue. In addition, the company's Xtampza ER will have an improved gross-to-net starting January 1st.

Collegium Pharmaceutical: Changing My Strategy After Q3 Earnings Beat

Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Dawn Schottlandt - Managing Director-Argot Partners Joe Ciaffoni - Chief Executive Officer Colleen Tupper - Chief Financial Officer Scott Dreyer - Chief Commercial Officer Conference Call Participants David Amsellem - Piper Sandler Tim Lugo - William Blair Brandon Folkes - Cantor Fitzgerald Serge Belanger - Needham & Company Greg Fraser - Truist Securities Oren Livnat - H.C. Wainwright Operator Greetings, and welcome to the Collegium Pharmaceutical Third Quarter 2022 Earnings Conference Call.

Collegium Pharmaceutical, Inc. (COLL) Q3 2022 Earnings Call Transcript

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -9.84% and 2.72%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Collegium Pharmaceutical (COLL) Lags Q3 Earnings Estimates

– Generated Record Net Revenue of $127.0 Million –

Collegium Reports Third Quarter 2022 Financial Results

STOUGHTON, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that it will report third quarter 2022 financial results after the market closes on Thursday, November 3, 2022. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET.

Collegium to Report Third Quarter 2022 Financial Results on November 3, 2022

Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q2 2022 Results Conference Call August 4, 2022 4:30 PM ET Company Participants Alex Dasalla - Head, IR Joseph Ciaffoni - CEO Colleen Tupper - CFO Scott Dreyer - CCO Conference Call Participants Greg Fraser - Truist David Amsellem - Piper Sandler Serge Belanger - Needham & Company Tim Lugo - William Blair Operator Greetings, and welcome to the Collegium Pharmaceutical Second Quarter 2022 Earnings Call. [Operator Instructions] Please note that this conference is being recorded.

Collegium Pharmaceutical, Inc. (COLL) CEO Joseph Ciaffoni on Q2 2022 Results - Earnings Call Transcript

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -90.08% and 0.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Collegium Pharmaceutical (COLL) Q2 Earnings Miss Estimates

– Generated Record Net Revenue of $123.5 Million –

Collegium Reports Second Quarter 2022 Financial Results

STOUGHTON, Mass., July 21, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that it will report second quarter 2022 financial results after the market closes on Thursday, August 4, 2022. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET.

Collegium to Report Second Quarter 2022 Financial Results on August 4, 2022

Shares of pain management drug concern Collegium Pharmaceutical have fallen over 40% as the biotech selloff, negative attitudes towards opiates, and patent cliffs have taken a toll. The company's recent purchase of BioDelivery Sciences provides it with complementary suite of assets, an entry into neurology, and $75 million of cost synergies.

Collegium Pharmaceutical: Oversold And Cheap

Alpha and Omega Semiconductor

DoorDash

Myers

Photronics

SpartanNash

Some very small stocks, micro-cap stocks, have good value and are overlooked and should be considered by investors to buy today. The post 7 Micro-Cap Stocks to Take a Chance on Now appeared first on InvestorPlace.

7 Micro-Cap Stocks to Take a Chance on Now

Collegium Pharmaceutical, Inc. (NASDAQ:COLL ) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Alex Dasalla - Head of IR & Corporate Communications Joe Ciaffoni - President and CEO Colleen Tupper - CFO Scott Dreyer - CCO Conference Call Participants David Amsellem - Piper Sandler Lachlan Hanbury-Brown - William Blair Serge Belanger - Needham & Co. Greg Fraser - Truist Securities Brandon Folkes - Cantor Fitzgerald Operator Greetings, and welcome to Collegium Pharmaceutical, Inc. First Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q1 2022 Results - Earnings Call Transcript

Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -38.14% and 6.41%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Collegium Pharmaceutical (COLL) Lags Q1 Earnings Estimates

- Generated Net Revenue of $83.8 Million -

Collegium Reports First Quarter 2022 Financial Results

STOUGHTON, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Tuesday, May 10, 2022 at 4:30 p.m. ET. The Company will discuss its first quarter 2022 financial results and provide a corporate update.

News for Collegium Pharmaceutical Stock (COLL)